Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single-institution experience.

PURPOSE: The aim of this study was to evaluate the rate of pathological response (PR), disease control and safety of neoadjuvant chemotherapy using oxaliplatin (OX) and 5-fluorouracil (5-FU) with concurrent radiotherapy for treating locally advanced rectal cancer. MATERIALS AND METHODS: Between November 2002 and December 2010, 90 patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy (CRT) were retrospectively analysed. All patients underwent preoperative radiotherapy (45 Gy in 1.8-Gy fractions) with concurrent OX (80 mg/m(2) i.v., day 1) and a 120-h continuous infusion of 5-FU (1,000 mg/m(2) per day). Surgery was performed within 6 weeks after completion of CRT treatment. RESULTS: Complete pathological response was obtained in six patients (6.7%), and 39 (43.3%) had their disease downstaged. The median follow-up period was 4.7 years (6 months to 9 years). Local recurrence occurred in two patients (2.2%), one of whom developed also liver metastases. Distant metastases not associated with local relapse occurred in 23 (25.6%) patients. Overall (OS) and disease-free (DFS) survival were 62.9% and 52.8%, respectively. CRT was well tolerated, with only one grade 3 (1.2%) haematological toxicity (neutropaenia). CONCLUSIONS: Neoadjuvant systemic chemotherapy based on OX and 5-UC associated with radiotherapy is well tolerated, with good results in terms of pathological response, disease control and survival, in rectal cancer patients.

Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.

Doxorubicin is highly effective and widely used in breast cancer; however, its use is limited by cardiotoxicity related to its cumulative dose. In previous studies, pegylated liposomal doxorubicin (PLD) has shown an acceptable toxicity profile with minimal cardiotoxicity. Between June 2006 and October 2009, 27 metastatic breast cancer patients were treated with first-line PLD and vinorelbine at the University of Florence, Radiotherapy Unit. PLD (30 mg/m²) was administered on day 1, and oral vinorelbine (60 mg/m²) was administered on days 1 and 8 of a 4-week cycle. All patients were previously treated with anthracycline-based adjuvant chemotherapy. Median age was 52 years (range 38-69) and median time to metastasis was 78.5 months. There were no treatment interruptions or discontinuation for cardiac toxicity and no treatment-related deaths. Grade 3 hematological toxicity was observed in 18.6% of patients, and 3.7% had grade 3 non-hematological adverse events. With a median follow-up of 13.2 months (range 3-33), median response duration was 6.1 months, and median PFS was 5.3 months. The overall clinical benefit rate was 55.5%. Our experience adds to evidence supporting the activity and cardiac safety of PLD and vinorelbine in metastatic breast cancer patients previously treated with anthracycline-based adjuvant chemotherapy.

Adjuvant trastuzumab in breast cancer: experience from the University of Florence.

The objective of this study was to evaluate the efficacy and tolerability profile of sequential trastuzumab in the adjuvant treatment of non-metastatic breast cancer. We analyzed 94 patients with non-metastatic breast cancer who underwent postoperative treatment between November 2003 and December 2008 at the University of florence. All patients received one year of sequential trastuzumab after adjuvant chemotherapy. Cardiac monitoring in our study consisted of assessment of left ventricular ejection fraction (lVef) by echocardiography at baseline, after the completion of chemotherapy, then every 3 months during trastuzumab treatment and every 6 months thereafter. 91.6% of patients were alive without evidence of distant or local relapse, while 8.4% developed disease recurrence. The cumulative incidence of cardiotoxicity was 14.5%. In our experience trastuzumab given postoperatively with adjuvant chemotherapy was well tolerated and produced optimal clinical results in terms of disease-free survival.

Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.

Ibandronate is an amino-bisphosphonate approved in metastatic breast cancer to reduce skeletal complications and to alleviate bone pain. we report our experience about the safety of oral ibandronate and review the literature.We treated 44 patients and administered 524 cycles of oral ibandronate (a single cycle was defined as a 50 mg capsule once daily for 28 days) with a median of 12 cycles (range 6-24). At a median follow-up of 18.5 months (range 6-28) the mean pain score decreased from 1.59 (SD+/-0.97) at baseline to 0.41 (SD+/-0.72) after 48 weeks of treatment. The mean analgesic score was 1.89 (SD+/-1.37) at baseline and 1.46 (SD+/-1.62) after 48 weeks of treatment. Ibandronate was generally well-tolerated; we had no Grade 3-4 adverse events. No patients had deterioration of renal function. No patients developed bisphosphonate-associated osteonecrosis of the jaw. Our experience confirmed that ibandronate may be a useful and safe co-analgesic to conventional treatments for bone pain in selected metastatic breast cancer patients.

Utilidad de los diferentes métodos no invasivos de predicción de fibrosis hepática en pacientes del País Vasco con hemocromatosis fenotípica / No disponible

Objetivo: determinar si el producto de la edad por la concentraciónde hierro hepático (índice de fibrosis) y los valores de plaquetas,ferritina y transaminasas están relacionados con el riesgode padecer fibrosis avanzada (F >= 3) en hemocromatosis.Métodos: estudio retrospectivo de 32 pacientes con hemocromatosishereditaria con expresión fenotípica. Todos los pacientesfueron biopsiados obteniéndose la concentración de hierrohepático.Resultados: en 7 pacientes se realizó RM (1,5T) con obtenciónde concentración de hierro hepático (protocolo de Alustiza).Biopsia hepática: en 23 pacientes fibrosis 0-2; en 9 fibrosis 3-4.El índice de fibrosis mostró una especificidad del 68%, sensibilidaddel 85,7%, VPP del 42,8% y VPN del 94,4% para fibrosis avanzada.La cifra de plaquetas (< 200.000) reveló un VPN 94,4%,ferritina (> 1.000) VPN 75% y el índice de fibrosis por RMN (puntocorte 480.000) VPN 80%. La combinación de los mismos, elíndice de fibrosis (por biopsia o por RM) con las transaminasas ylas plaquetas con las transaminasas, reveló un VPN del 100%.Conclusiones: el índice de fibrosis (> 480.000) y las plaquetas(< 200.000) tienen la mayor sensibilidad para predecir fibrosisde alto grado. Un resultado negativo en ambos permite descartarfibrosis significativa en el 94% de los casos. La RM permite unabuena predicción de fibrosis

Objective: to determine whether the product of multiplyingage by liver iron concentration (LIC) (fibrosis index; cut-off,480,000), platelets, transaminases, and ferritin values are relatedto the risk of high grade fibrosis.Methods: a retrospective study of 32 patients with hereditaryhemochromatosis (HH) with phenotypic expression. All patientshad a liver biopsy with LIC.Results: in 7 patients a magnetic resonance imaging (MRI)scan (1.5 T) was obtained with LIC following Alustiza’s protocol.Liver biopsy: fibrosis grade (F) 0-2 in 23 patients; F 3-4 in 9. Fibrosisindex (FI) showed a specificity of 68%, sensitivity of 85.7%,positive predictive value (PPV) of 42.8%, and negative predictivevalue (NPV) of 94.4% for high-grade fibrosis. Platelet count(< 200,000) revealed a NPV of 94.7% for F3-4. Aspartatetransaminase (AST) levels above the upper limit of normal showeda NPV of 94.4%; ferritin levels (> 1,000) a NPV of 75%, andMRI-derived LIC x age (> 480,000) a NPV of 80%. The combinationof FI (either by biopsy or MRI) with transaminases, and ofplatelets with transaminases revealed a NPV of 100%.Conclusions: FI > 480,000 and platelets < 200,000 havethe highest sensitivity for high-degree fibrosis prediction. A negativeresult allows to discard significant fibrosis in 94% of cases.MRI allows a good fibrosis prediction

[Utility of various non-invasive methods for fibrosis prediction among Basque Country patients with phenotypic hemochromatosis]. / Utilidad de los diferentes métodos no invasivos de predicción de fibrosis hepática en pacientes del País Vasco con hemocromatosis fenotípica.

OBJECTIVE: To determine whether the product of multiplying age by liver iron concentration (LIC) (fibrosis index; cut-off, 480,000), platelets, transaminases, and ferritin values are related to the risk of high grade fibrosis. METHODS: A retrospective study of 32 patients with hereditary hemochromatosis (HH) with phenotypic expression. All patients had a liver biopsy with LIC. RESULTS: In 7 patients a magnetic resonance imaging (MRI) scan (1.5 T) was obtained with LIC following Alustiza's protocol. Liver biopsy: fibrosis grade (F) 0-2 in 23 patients; F 3-4 in 9. Fibrosis index (FI) showed a specificity of 68%, sensitivity of 85.7%, positive predictive value (PPV) of 42.8%, and negative predictive value (NPV) of 94.4% for high-grade fibrosis. Platelet count ( < 200,000) revealed a NPV of 94.7% for F3-4. Aspartate transaminase (AST) levels above the upper limit of normal showed a NPV of 94.4%; ferritin levels (> 1,000) a NPV of 75%, and MRI-derived LIC x age (> 480,000) a NPV of 80%. The combination of FI (either by biopsy or MRI) with transaminases, and of platelets with transaminases revealed a NPV of 100%. CONCLUSIONS: FI > 480,000 and platelets < 200,000 have the highest sensitivity for high-degree fibrosis prediction. A negative result allows to discard significant fibrosis in 94% of cases. MRI allows a good fibrosis prediction.

Use of tamoxifen in pT1a-pT1b, pN0 breast cancer.

PURPOSE: To evaluate if in low-risk breast cancer patients (pT1a-pT1b, pN0) tamoxifen can reduce local recurrence and improve survival. METHODS: Retrospectively 700 patients were analyzed. All patients were treated from 1980 to 2003 with conservative surgery plus radiotherapy at the University of Florence. No patients were treated with adjuvant chemotherapy. Tamoxifen was prescribed in 359 patients (51.3%). The crude probability of survival (or local recurrence) was estimated by using Kaplan-Meier method, and survival (or local recurrence) comparisons were carried out using Cox proportional hazard regression models. RESULTS: The univariate analysis for specific survival showed that only histological type and local recurrence were significant prognostic factors (log rank test: p=0.02 and p<0.0001, respectively). The Cox regression model by stepwise selection confirmed lobular histological type (p=0.008; HR: 3.83, 95% CI: 1.31-11.21) and local recurrence (p<0.001; HR: 9.05, 95% CI: 3.05-26.82) as independent prognostic factors for disease specific survival. For local disease free survival, multivariate analysis did not show any significant parameters. CONCLUSION: In our series tamoxifen did not seem to improve disease specific survival and local disease specific survival. The number of events in terms of death for cancer or in terms of local recurrence is too small in this group of patients. However, according to our results we suggest not to prescribe tamoxifen in patients affected by pT1a-pT1b, pN0 breast cancer.

Uterine sarcoma: twenty-seven years of experience.

PURPOSE: A correlation of treatment for uterine sarcoma with outcome, prognostic importance of pathology, and clinical parameters. PATIENTS AND METHODS: One hundred forty-one patients (median age: 56 years, range: 19-85 years) with a histologically verified uterine sarcoma were identified from a database compiled at the Royal Marsden Hospital and the University of Florence between 1974 and 2001. Seventy-two patients had leiomyosarcoma, 42 had mixed müllerian tumors, 22 had endometrial stromal sarcoma, 1 hemangiopericytoma, 1 rhabdomyosarcoma, and 3 patients had unspecified sarcoma. According to FIGO classification, Stage I, II, III, and IV tumors were identified in 71, 13, 31, and 26 patients, respectively. RESULTS: At the time of analysis, 73.7% of patients were dead, and 26.3% were alive with a median survival of 2 years from initial diagnosis. Univariate analysis for cause-specific survival demonstrated statistical significance for histology (p = 0.02), grade (p = 0.003), stage (p = 0.007), and age (p = 0.02). Multivariate analysis demonstrated significant prognostic values for stage (p = 0.02) and histology (p = 0.05) only. Postoperative radiotherapy with a total dose higher than 50 Gy seems to be significant (p = 0.001) in reducing local recurrence. CONCLUSIONS: Our data favor treatment for Stages I, II, and III of uterine sarcoma with radical surgery plus radical dose irradiation comprising both external beam radiotherapy and brachytherapy.

[Role of adjuvant radiotherapy in the treatment of rectal carcinoma]. / Ruolo della radioterapia adiuvante nel trattamento del carcinoma rettale.

Radiotherapy (RT) either pre or postoperative is widely accepted as the standard adjuvant treatment in rectal carcinoma invading the perirectal tissues. The main effect of RT was to decrease the incidence of local recurrence by 30%-50%; there was however no evidence of any impact on survival. With preoperative RT a large range of doses was tested; a dose of 35 Gy or more with fractions of 1.8-2.0 Gy five times per week (or a biologically equivalent regimen) is required to affect the local recurrence rate; with postoperative RT a more uniform dose of 45-50 Gy in 5 five weeks was used. Wether RT is better to be given pre or postoperatively has been the object of a continuing debate. The preoperative option seems at present preferable: the main advantages of this option are the lower morbidity and the possible increase of sphincter saving surgery; the availability of the intrarectal imaging modalities made the clinical staging very reliable, eliminating the major concern of preoperative RT represented by the possible overtreatment of early intraparietal tumours. For tumours located in the range of applicability of intrarectal US or MR (extraperitoneal rectum) preoperative RT should be considered the first choice adjuvant treatment. For tumours located in the intraperitoneal part of the rectum postoperative RT, on the basis of pathological staging, is probably preferable. Two randomized trials reported an improvement of the overall survival when postoperative RT was given concomitantly with 5 Fluorouracil but at the expense of a higher morbidity and a lower compliance. The most promising approach to be explored seems therefore the concomitant combination of preoperative RT and 5 Fluorouracil. Future studies should also define the more effective modality of this combination and wether 5 Fluorouracil has to be given alone or combined with other drugs.